Recent Developments in Anxiety Disorders
Pp. 17-40 (24)
David M. Christmas, Geetha Menon and Sean D. Hood
Anxiety disorders are common and debilitating mental illnesses. Current pharmacological treatments are beset by problems of poor efficacy and side effect profiles. Increasing understanding of novel neurotransmitter systems and the interplay between these systems is broadening the scope of anxiolytic drug treatment. This article aims to describe the areas of current interest and possible future development of anxiolytic drugs by outlining recent patents in this field. A patent database was searched for 55 neurotransmitters, synonyms as well as compounds of recent known interest from May 2003 to July 2009. The internet resources Pubmed and Google Scholar were searched for peer reviewed literature using the same search parameters. Results were grouped into neurotransmitter systems to present an overview of recent developments in the neuropharmacology of anxiety disorders.
Patent, anxiety, serotonin, GABA, glutamate, neuropeptide, cannabinoid, novel, CCK, CRF, vasopressin, neurokinin, oxytocin, galanin
School of Psychiatry and Clinical Neurosciences (M521), University of Western Australia, Perth, Australia